机构：[1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University Luzhou, People’s Republic of China.[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, People’s Republic of China.[3]Department of Nuclear Medicine, People’s Hospital of Deyang City, Deyang, People’s Republic of China.[4]Department of Nuclear Medicine, The People’s Hospital of Tongliang District, Chongqing, People’s Republic of China.[5]Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang, People’s Republic of China.[6]Key Laboratory of Nuclear Medicine and Molecular Imaging of Sichuan Province, Mianyang, People’s Republic of China.
Objective:
The purpose of this study was to explore the potential use of 177Lu-diethylenetriamine penta-acetic acid-deoxyglucose (177Lu-DTPA-DG) as a radiopharmaceutical for hepatic tumor treatment.
Methods:
Lutetium-177 (177Lu) was labeled with DTPA-DG by adding 2 mCi 177LuCl3 to 0.05 mg DTPA-DG (pH 5-6) at room temperature for 1 h. The quality of the177Lu-DTPA-DG solutions was determined by thin-layer chromatography and high-performance liquid chromatography. Cellular uptake studies with 18F-fluorodeoxyglucose (FDG), 177Lu-DTPA-DG and 177Lu-DTPA and a blocking study with 1.0 mg d-glucose were performed. Biodistribution, imaging, and radiotherapy studies of 177Lu-DTPA-DG were performed with the SMMC-7721 model.
Results:
177Lu-DTPA-DG had a high radiochemical purity (>97%). The cellular uptake of 177Lu-DTPA-DG was much higher than that of the 177Lu-DTPA. The biodistribution of 177Lu-DTPA-DG demonstrated that the complex accumulated in the tumor with high tumor/blood and tumor/muscle ratios. The tumors in mice in the 177Lu-DTPA-DG group clearly displayed the high uptake of 177Lu-DTPA-DG. After radiotherapy with 177Lu-DTPA-DG, tumor growth decreased, and the overall survival was longer than that in the 177LuCl3 group (268.58 ± 17.96 mm3 vs. 507.43 ± 55.72 mm3, p = 0.002) and the normal saline group (268.58 ± 17.96 mm3 vs. 483.68 ± 27.51 mm3, p < 0.05).
Conclusions:
This preliminary study suggests that 177Lu-DTPA-DG has the potential to become a liver radiopharmaceutical agent and should be further investigated.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|4 区医学
小类|4 区肿瘤学4 区医学：研究与实验4 区药学4 区核医学
最新[2023]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区肿瘤学4 区药学4 区核医学
第一作者：
第一作者机构：[1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University Luzhou, People’s Republic of China.[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, People’s Republic of China.[3]Department of Nuclear Medicine, People’s Hospital of Deyang City, Deyang, People’s Republic of China.
通讯作者：
通讯机构：[1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University Luzhou, People’s Republic of China.[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, People’s Republic of China.[*1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University,No. 25, Taiping Street, Luzhou, Sichuan 646000, People’s Republic of China
推荐引用方式(GB/T 7714)：
Ling Zhou,Li Chen,Ling Yang,et al.Preliminary Studies of 177Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice.[J].Cancer biotherapy & radiopharmaceuticals.2020,35(1):33-40.doi:10.1089/cbr.2019.2903.
APA：
Ling Zhou,Li Chen,Ling Yang,Liang Cai,Lin Liu...&Yue Chen.(2020).Preliminary Studies of 177Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice..Cancer biotherapy & radiopharmaceuticals,35,(1)
MLA：
Ling Zhou,et al."Preliminary Studies of 177Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice.".Cancer biotherapy & radiopharmaceuticals 35..1(2020):33-40
